Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study

Beata Kotowicz; Anna Dańska-Bidzińska; Małgorzata Fuksiewicz; Anna Nasierowska-Guttmejer; Dorota Raczkiewicz; Mariusz Gujski; Szymon Piątek; Mariusz Bidziński

doi:10.12659/MSM.941562

07 December 2023 : Clinical Research

Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study

Beata Kotowicz

^1ACDEF*, Anna Dańska-Bidzińska

^2ABDEG, Małgorzata Fuksiewicz

^1BCDE, Anna Nasierowska-Guttmejer

^3BC, Dorota Raczkiewicz

^4C, Mariusz Gujski

^5BEF, Szymon Piątek

^6B, Mariusz Bidziński

^6AEG

DOI: 10.12659/MSM.941562

Med Sci Monit 2023; 29:e941562

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 2 ROC curves of CA125 and inflammatory biomarkers (A) and VEGF and their receptors, (B) assays in uterine sarcoma patients vs control group. Created using MedCalc statistical software.

Back to the Article

Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study

Your Privacy